We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

bioMérieux Finalizes Acquisition of BioFire

By LabMedica International staff writers
Posted on 16 Jan 2014
Print article
bioMérieux (Paris, France), a leader in the field of in vitro diagnostics, has finalized its acquisition of 100% ownership in BioFire Diagnostics Inc. (Salt Lake City, UT, USA) a privately held US-based company specialized in molecular biology. With this acquisition, bioMérieux consolidates its position in infectious disease diagnostics and strengthens its presence in the United States.

The transaction includes a USD 450 million acquisition price and the company's net financial debt (around USD 35 million), representing a total of about USD 486 million. This acquisition will be essentially funded through bioMérieux's inaugural USD 408.5-million issue of seven-year bonds.

BioFire has developed, produced, and marketed a number of automated polymerase chain reaction (PCR) molecular biology systems. More recently, BioFire developed FilmArray, a CE-marked and US Food and Drug Administration (FDA; Silver Spring, MD, USA)-cleared multiplex PCR system that integrates all molecular diagnostics steps—sample preparation, amplification, detection, and analysis—into one system.

FilmArray, has introduced the syndromic approach—a new medical approach based on analyzing a syndrome i.e., a set of symptoms and, with a single reagent, identifying the disease-causing organisms responsible for this syndrome, whether they are viruses or bacteria—to infectious disease molecular diagnostics, creating a new standard in this market with its essential combination of speed, accuracy, ease-of-use, and comprehensiveness in one single assay. It allows hospitals to perform the molecular biology tests available on its menu in the hospital laboratory, thereby enabling faster and more efficient medical decision-making. FilmArray as of today has two CE-marked and FDA-cleared panels —the respiratory panel and the blood culture identification panel.

The two companies present strong strategic synergies, especially in marketing, manufacturing, and innovation. FilmArray is a key differentiating asset in the development of bioMérieux's franchise in infectious disease diagnostics, its primary area of expertise. FilmArray will benefit from the bioMérieux's worldwide commercial network. Additionally, bioMérieux will contribute its capabilities to the automation of reagent production, thereby optimizing manufacturing costs.

BioFire's site in Salt Lake City will become bioMérieux's hub for its expansion in molecular biology and R&D teams from the two companies will contribute to the development of new panels, creating very attractive prospects for the future.

bioMérieux and BioFire will start the integration process, focusing on leveraging the positive synergies between both companies, to drive FilmArray sales and menu expansion. In order to meet the expectations of BioFire's biodefense customers in the United States, a wholly owned subsidiary dedicated to the biodefense activities will be established. All the BioFire personnel, activities, and equipment associated with the defense business are physically transferred to a protected and separate site in Salt Lake City.

Jean-Luc Belingard, chairman and CEO of bioMérieux, commented: "The acquisition of BioFire creates strong growth opportunities. FilmArray meets perfectly the growing hospital laboratory demand for high medical value solutions in infectious disease diagnostics, thus ideally complementing our current product offering, especially for emergency situations and critical care."

Related Links:

bioMérieux
BioFire Diagnostics Inc.
US Food and Drug Administration (FDA)


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.